A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV).

Trial Profile

A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV).

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Sep 2015

At a glance

  • Drugs Asvasiran sodium (Primary)
  • Indications Bronchiolitis obliterans; Respiratory syncytial virus infections
  • Focus Therapeutic Use
  • Sponsors Alnylam Pharmaceuticals
  • Most Recent Events

    • 03 Sep 2015 Results published in the Journal of Heart and Lung Transplantation
    • 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
    • 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top